Results 81 to 90 of about 11,703 (213)

Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures

EBioMedicine
Summary Background Pancreatic ductal adenocarcinoma (PDAC) is a tumour entity with unmet medical need. To assess the therapeutic potential of oncolytic virotherapy (OVT) against PDAC, different oncolytic viruses (OVs) are currently investigated in ...
Theresa E. Schäfer, L. Knol, Ferdinand V. Haas, A. Hartley, Sophie C.S. Pernickel, Attila Jády, Maximiliane S. C. Finkbeiner, Johannes Achberger, Stella Arelaki, Živa Modic, Katrin Schröer, Wenli Zhang, Barbara Schmidt, P. Schuster, S. Haferkamp, J. Doerner, Florian Gebauer, M. Ackermann, H. Kvasnicka, Amit A. Kulkarni, Selas T F Bots, V. Kemp, L. Hawinkels, A. Poetsch, R. Hoeben, A. Ehrhardt, Antonio Marchini, G. Ungerechts, Claudia R. Ball, C. E. Engeland   +29 more
semanticscholar   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, EarlyView.
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

Virotherapy – cancer targeted pharmacology

Drug Discovery Today, 2012
Building on their success in vaccination, many groups are now exploring the use of viruses as anticancer agents. In general, viral therapeutics provide the possibility to express anticancer proteins directly at the tumour site, decreasing exposure to normal tissue during delivery and maximising therapeutic index.
Tedcastle, A, Cawood, R, Di, Y, Fisher, K, Seymour, L   +4 more
openaire   +3 more sources

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

International Journal of Molecular Sciences
Glioblastoma is one of the most malignant and aggressive tumors of the central nervous system. Despite the standard therapy consisting of maximal surgical resection and chemo- and radiotherapy, the median survival of patients with this diagnosis is about
A. Ageenko, N. Vasileva, Vladimir Richter, E. Kuligina   +3 more
semanticscholar   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

Nature Communications
The presence of heterogeneity in responses to oncolytic virotherapy poses a barrier to clinical effectiveness, as resistance to this treatment can occur through the inhibition of viral spread within the tumor, potentially leading to treatment failures ...
N. Kurmasheva, Aida Said, Boaz Wong, Priscilla Kinderman, Xiaoying Han, A. H. F. Rahimic, Alena Kress, Madalina E. Carter-Timofte, Emilia Holm, D. van der Horst, Christoph F Kollmann, Zhenlong Liu, Chen Wang, Huy-Dung Hoang, Elina Kovalenko, Maria Chrysopoulou, Krishna S. Twayana, Rasmus N Ottosen, Esben B. Svenningsen, F. Begnini, Anders E Kiib, Florian E H Kromm, Hauke J. Weiss, Daniele Di Carlo, M. Muscolini, Maureen Higgins, Mirte van der Heijden, A. Bardoul, T. Tong, A. Ozsvar, W. Hou, Vivien R. Schack, C. K. Holm, Yunan Zheng, Melanie Ruzek, Joanna M Kalucka, L. de la Vega, W. Elgaher, A. Korshoej, Rongtuan Lin, John Hiscott, Thomas B. Poulsen, L. O'Neill, D. Roy, Markus M. Rinschen, Nadine van Montfoort, J. Diallo, H. Farin, Tommy Alain, D. Olagnier   +49 more
semanticscholar   +1 more source

Oncolytic Vaccinia Virus‐HSP70‐shRNA Amplifies Viral Replication, ROS/Autophagy, and Immunity to Fight Colorectal Cancer

Cancer Science, EarlyView.
OncoVV‑shHSP70, a vaccinia virus silencing HSP70, demonstrated potent antitumor efficacy in colorectal cancer cell lines, as well as in syngeneic, xenograft, and humanized mouse models. In cell lines, oncoVV‑shHSP70 promoted viral oncolysis and cytokine production through a self‑reinforcing cycle of ROS‑autophagy. In both CT26 and SW620‑humanized mouse
Rentao Yuan, Ruikang Liu, Fangying Shao, Zheqi Cai, Yingfei Fang, Kan Chen, Yanrong Zhou, Ting Ye, Gongchu Li   +8 more
wiley   +1 more source

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Molecular Therapy: Oncolytics, 2019
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng, Jianhan Huang, Aiping Tong, Hui Yang   +3 more
doaj   +1 more source

The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Cancer Gene Therapy
Colorectal cancer (CRC) is known to be resistant to immunotherapy. In our phase-I clinical trial, one patient achieved a 313-day prolonged response during the combined treatment of oncolytic virotherapy and immunotherapy.
Hangyu Zhang, Yiqing Ren, Feiyu Wang, Xiaoxuan Tu, Z. Tong, Lulu Liu, Yi Zheng, Peng Zhao, Jinlin Cheng, Jianwen Li, Weijia Fang, Xia Liu   +11 more
semanticscholar   +1 more source

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source